Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Pioneering Oxford research to tackle vision loss is set to feature on the BBC’s One Show this week.

The BBC One programme is to feature the story of a patient from Reading who has choroideremia, a progressive loss of vision.

The patient took part in an ongoing gene therapy trial that is being performed at the John Radcliffe Hospital by the Nuffield Laboratory of Ophthalmology, led by University of Oxford Professor and OUH Consultant Ophthalmologist Robert MacLaren.

Choroideremia is a currently incurable genetic eye disorder caused by a mutation in a single gene.The new treatment seeks to replace a ‘normal’ version of that gene, offering the potential to halt or even partially reverse vision loss.

The treatment is delivered to the eye by an injection, underneath the retina, of a virus that contains the correct version of the gene. The injection places the viral particles in the correct anatomical location, and the virus itself delivers the correct copy of the gene into the dysfunctional cells.

A number of patients in this ongoing trial have already been enrolled and received gene therapy. If successful, this technique may be applied more widely to other genetic retinal diseases.

The programme is planned to broadcast on Wednesday, July 8 from 7pm.

Similar stories

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

COVID-19 infection has greater risk than vaccines of causing very rare neurological events

Research reveals risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.